E-Mentoring Program for Graduate and Undergraduate Nursing Students: Outline of Program Modules and Pre and Post Survey Templates

Many new graduate nurses face difficulties in their transition to professional practice. To help mitigate these difficulties, socialization through social supports and mentoring are critical to facilitate entry to practice (Robbio, 2018) and may be realized through opportunities for empathetic, authentic, and relational mentoring to address ongoing issues, such as isolation and a lack of social connectivity and mental wellbeing, faced by nursing students (Cengiz et al., 2021). Traditional in-person mentoring may encounter barriers, such as unsupportive work environments, lack of mentor access, heavy workloads and location and distance constraints. To address these limitations, an e-mentoring program for nursing students by nursing students was developed as a viable transitional strategy. This document provides individuals with access to the following openly licensed components from York University’s E-Mentoring Program: Partnering Graduate Nursing Students and Undergraduate Nursing Students: A list of the modules in the fully online program; Access to the survey instruments that were developed and administered to e-mentees and e-mentors prior to the program and at the completion of the program.Academic Innovation Fun

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

This study compared the efficacy of a tetrahydrocannabinol:cannabidiol (THC:CBD) extract, a nonopioid analgesic endocannabinoid system modulator, and a THC extract, with placebo, in relieving pain in patients with advanced cancer. In total, 177 patients with cancer pain, who experienced inadequate analgesia despite chronic opioid dosing, entered a two-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial. Patients were randomized to THC:CBD extract (n = 60), THC extract (n = 58), or placebo (n = 59). The primary analysis of change from baseline in mean pain Numerical Rating Scale (NRS) score was statistically significantly in favor of THC:CBD compared with placebo (improvement of -1.37 vs. -0.69), whereas the THC group showed a nonsignificant change (-1.01 vs. -0.69). Twice as many patients taking THC:CBD showed a reduction of more than 30% from baseline pain NRS score when compared with placebo (23 [43%] vs. 12 [21%]). The associated odds ratio was statistically significant, whereas the number of THC group responders was similar to placebo (12 [23%] vs. 12 [21%]) and did not reach statistical significance. There was no change from baseline in median dose of opioid background medication or mean number of doses of breakthrough medication across treatment groups. No significant group differences were found in the NRS sleep quality or nausea scores or the pain control assessment. However, the results from the European Organisation for Research and Treatment of Cancer Quality of Life Cancer Questionnaire showed a worsening in nausea and vomiting with THC:CBD compared with placebo (P = 0.02), whereas THC had no difference (P = 1.0). Most drug-related adverse events were mild/moderate in severity. This study shows that THC:CBD extract is efficacious for relief of pain in patients with advanced cancer pain not fully relieved by strong opioids. © 2010 U.S. Cancer Pain Relief Committee.SCOPUS: ar.jinfo:eu-repo/semantics/publishe